A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00050427

Recruitment Status : Completed

First Posted : December 18, 2002

Last Update Posted : April 28, 2011

Sponsor:

Collaborator:

PharmaMar

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study Description

Brief Summary:

The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced breast cancer.

Condition or disease	Intervention/treatment	Phase
Breast Neoplasms Neoplasms Neoplasms by Site Breast Diseases Skin Diseases	Drug: ET743	Phase 2

Detailed Description:

Patients will be enrolled in the study after all study specific-entry criteria are met and informed consent is obtained. Patients will be required to attend regular clinic visits to receive study medication and have their status monitored. Patients will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the study physician (Investigator) conducting this study. Trabectedin 580 mcg/m2 once weekly for 3 consecutive weeks (Treatment A) or 1,300 mcg/m2 once every 21 days (Treatment B) will be given to patients as a 3-hour intravenous (i.v). infusion via a central venous catheter which is a tube placed into a large vein that is used to administer medications. All patients will be given dexamethasone 10 mg i.v. 30 minutes before each trabectedin infusion. Patients may receive multiple cycles of trabectedin in the absence of disease progression.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	53 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer
Study Start Date :	December 2002
Actual Study Completion Date :	December 2006

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Breast cancer

MedlinePlus related topics: Breast Cancer

Drug Information available for: Trabectedin

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 001 ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.	Drug: ET743 580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
Experimental: 002 ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.	Drug: ET743 1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.

Outcome Measures

Primary Outcome Measures :

Number of patients with objective response in each treatment arm. [ Time Frame: Up to approximately 52 weeks ]

Secondary Outcome Measures :

Progression-free survival (PFS) [ Time Frame: Up to approximately 52 weeks ]
Time to progression (TTP) [ Time Frame: Up to approximately 52 weeks ]
Overall survival (OS) [ Time Frame: Up to approximately 52 weeks ]
The number of patients with treatment-emergent adverse events [ Time Frame: Up to approximately 52 weeks ]
Concentrations of trabectedin in plasma as a measure of the pharmacokinetics of trabectedin [ Time Frame: During the first two 28-day treatment cycles ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of advanced breast cancer
Prior therapy with anthracycline and taxane (2 types of chemotherapy drugs)
At least one measureable tumor lesion
Adequate bone marrow, hepatic and renal function
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Exclusion Criteria:

Known hypersensitivity to any components of the i.v. formulation of ET-743 or dexamethasone
Pregnant or lactating women
Known metastases (spread) of cancer to the central nervous system
History of another neoplastic disease unless in remission for five years or more.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00050427

Sponsors and Collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

PharmaMar

Investigators

Layout table for investigator information

Study Director:	Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens. Clin Breast Cancer. 2014 Dec;14(6):396-404. doi: 10.1016/j.clbc.2014.06.006. Epub 2014 Aug 15.

Layout table for additonal information

Responsible Party:	Sr Dir Clinical Research, Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
ClinicalTrials.gov Identifier:	NCT00050427
Obsolete Identifiers:	NCT01328327
Other Study ID Numbers:	CR004525 ET743-INT-3
First Posted:	December 18, 2002 Key Record Dates
Last Update Posted:	April 28, 2011
Last Verified:	April 2011

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:


Trabectedin Yondelis ET743 Advanced breast cancer	Breast Cancer Antineoplastic Agents, Alkylating Agents Molecular Mechanisms of Pharmacological Action

Additional relevant MeSH terms:

Layout table for MeSH terms

Breast Neoplasms Neoplasms by Site Skin Diseases Breast Diseases Neoplasms Dexamethasone Dexamethasone acetate Trabectedin BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents	Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Alkylating Alkylating Agents

To Top